US Stock MarketDetailed Quotes

INO Inovio Pharmaceuticals

Watchlist

1.7400
-0.0100-0.57%

Trading Mar 27 14:26 ET

63.80MMarket Cap-0.44P/E (TTM)

Inovio Pharmaceuticals Stock Forum

Teddy123

Mar 19 08:41

INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

$Inovio Pharmaceuticals (INO.US)$
INOVIO Slashes Losses by $28M as RRP Treatment Shows 50% Complete Response Rate

Teddy123

Mar 14 13:17

INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19

$Inovio Pharmaceuticals (INO.US)$
INOVIO's Revolutionary COVID-19 Antibody Treatment Maintains 100% Efficacy for 72 Weeks

Jaguar8

Mar 14 06:30

🟡Watchlist, MARCH 14,2025, Friday. NFA -DrJag8

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you...

Jaguar8

Mar 14 06:15

NEWS

$Inovio Pharmaceuticals (INO.US)$
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
Thursday, 13th March at 6:15 pm
• Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint
• No anti-drug antibodies (ADA): no immune rejection of the DMAbs was detected across ~1,000 blood samples, unlike other gene-based antibod...

Lnova

Feb 23 05:34

Phase 1/2 Data to be Presented Feb 23-26

$Inovio Pharmaceuticals (INO.US)$
“Phase 1/2 data due to be presented at AACR-IO on February 23-26, 2025. BLA submission due in mid-2025. New immunology on Phase 1/2 data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment, noted November 13, 2024.”
｡ﾟ* ҉* ੈ‧₊ ｡ﾟnot financial advice

Teddy123

Feb 12 21:21

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

$Inovio Pharmaceuticals (INO.US)$
Breakthrough RRP Treatment Slashes Surgery Need: 28% of Patients Now Surgery-Free in Nature Communications Study

Trytosaveabit

Feb 12 21:09

Update

$Inovio Pharmaceuticals (INO.US)$ Benzinga· 4 mins ago
INOVIO Announces Phase 1/2 Trial Results Of INO-3107 For Recurrent Respiratory Papillomatosis With 81% Of Patients Requiring Fewer Surgeries; Plans BLA Submission In Mid-2025 For FDA Accelerated Approval, Aiming To Achieve First US DNA Medicine Approval